Determining Treatment Options for Select Subsets of Neuroendocrine Tumors

Thor Halfdanarson, MD, medical oncologist at Mayo Clinic, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.

Halfdanarson oeps that community oncologists understand that not all grade 3 or high-grade NETs are the same, nor should they be treated the same. There is, for example, a subset of patients with high-grade NETs that needs to be treated aggressively with cytotoxic chemotherapy, while another subset does not require such aggressive, upfront therapy.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/